Curis Stock Price, News & Analysis

Curis (NASDAQ: CRIS) has announced it will release its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. The biotechnology company, which focuses on developing emavusertib (CA-4948), an oral IRAK4 inhibitor, will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the investor section of the Curis website.

Curis (NASDAQ: CRIS) has announced a $12.1 million financing through a registered direct offering and concurrent private placement. The company will issue 2,398,414 shares of common stock and unregistered warrants to purchase an equal number of shares. The warrants have an exercise price of $4.92 per share, are immediately exercisable, and expire in five years. The combined purchase price is $5.045 per share and warrant. The proceeds will fund research, development, working capital, and general corporate purposes. The offering is expected to close around October 30, 2024.

Curis, Inc. (NASDAQ: CRIS) announces the 3rd Annual Symposium on IRAK4 in Cancer, scheduled for September 26, 2024. The virtual event, hosted by Dr. Eric S. Winer and Dr. Grzegorz S. Nowakowski, will focus on IRAK4 as an emerging target in treating hematologic malignancies and solid tumors. The symposium will feature updated data for 10 evaluable R/R PCNSL patients as of July 10, 2024. Curis aims to enroll 15-20 patients in the PCNSL study by year-end.

The event will bring together experts to discuss the potential of IRAK4 inhibition in cancer, including current clinical studies of emavusertib (CA-4948), Curis's orally available, small molecule IRAK4 inhibitor. Presentations will cover the biology of the IRAK4 pathway and its inhibition in cancer therapy development. The symposium is free and open to the public, offering insights into this promising area of oncology research.

Curis Inc (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. James Dentzer, President and CEO of Curis, will engage in a fireside chat on September 17, 2024, at 4:15 PM ET.

The event will be accessible via webcast through the Cantor link and on the Curis website in the Investors section. This participation underscores Curis's commitment to engaging with the investment community and showcasing its progress in developing innovative therapies for cancer treatment.

Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its participation in two upcoming healthcare conferences in September 2024. James Dentzer, President and CEO, will represent Curis at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11): Company presentation on Sept. 11 at 1:00 pm ET.

2. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19): Fireside chat on Sept. 17 at 3:05 pm ET.

Webcasts for both presentations will be available on the Curis website in the 'Investors' section, providing investors with opportunities to gain insights into the company's progress and strategy.

Curis Inc. (NASDAQ: CRIS) reported Q2 2024 financial results and operational updates. Key highlights include:

1. European Commission granted Orphan Drug Designation to emavusertib for PCNSL treatment.

2. Initial data for 15-20 R/R PCNSL patients expected by late 2024.

3. Positive preliminary data in R/R AML patients with FLT3 and SF mutations.

4. Q2 2024 net loss of $11.8 million ($2.03 per share) vs $12.0 million ($2.47 per share) in Q2 2023.

5. Revenues increased to $2.5 million in Q2 2024 from $2.2 million in Q2 2023.

6. Cash position of $28.4 million as of June 30, 2024, expected to fund operations into Q1 2025.

Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its plans to release second quarter 2024 financial and operating results on August 1, 2024, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live audio webcast will be available on the investor section of the Curis website, with a replay accessible later at www.curis.com.

Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.

Curis announced that its independent Compensation Committee approved an inducement stock option grant for a new employee. The grant, effective July 1, 2024, allows the employee to purchase 25,000 shares of Curis common stock at the closing price on the grant date. The stock options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% vesting every three months thereafter. This grant is outside of the company's existing stock incentive plan and aims to encourage the new employee to join Curis.